Robert Ragusa
On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026.
Highest-materiality recent filing
Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M
Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.
Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement
Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.
Alamar Biosciences closes IPO of 12.9M shares at $17.00, raising ~$219.9M
Completed IPO of 12,937,500 shares of common stock at $17.00 per share, including full exercise of underwriters' option for 1,687,500 shares.
On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026.
Max materiality 0.85 · Median 0.78 · Most common event leadership